Inorg. Chem. 1996, 35, 7377-7383
7377
Syn-Anti Isomerism in a Mixed-Ligand Oxorhenium Complex, ReO[SN(R)S][S]
M. S. Papadopoulos, I. C. Pirmettis, M. Pelecanou, C. P. Raptopoulou, A. Terzis,
C. I. Stassinopoulou, and E. Chiotellis*
Institutes of Radioisotopes-Radiodiagnostic Products, Biology, and Materials Science,
NCSR “Demokritos”, POB 60228, 15310, Aghia Paraskevi, Athens, Greece
ReceiVed April 17, 1996X
The simultaneous action of the tridentate ligand (C2H5)2NCH2CH2N(CH2CH2SH)2 and the monodentate coligand
HSC6H4OCH3 on a suitable ReO3+ precursor results in a mixture of syn- and anti-oxorhenium complexes, ReO-
[(C2H5)2NCH2CH2N(CH2CH2S)2] [SC6H4OCH3], in a ratio of 25/1. The complexes are prepared by a ligand
exchange reaction using ReO(eg)2 (eg ) ethylene glycol), ReOCl3(PPh3)2, or Re(V)-citrate as precursor. Both
complexes have been characterized by elemental analysis, FT-IR, UV-vis, X-ray crystallography, and NMR
spectroscopy. The syn isomer C17H29N2O2S3Re crystallizes in the monoclinic space group P21/n, a ) 14.109(4)
Å, b ) 7.518(2) Å, c ) 20.900(5) Å, â ) 103.07(1)°, V ) 2159.4(9) Å3, Z ) 4. The anti isomer C17H29N2O2S3-
Re crystallizes in P21/n, a ) 9.3850(7) Å, b ) 27.979(2) Å, c ) 8.3648(6) Å, â ) 99.86(1)°, V ) 2163.9(3) Å3,
Z ) 4. Complete NMR studies show that the orientation of the N substituent chain with respect to the RedO
core greatly influences the observed chemical shifts. Complexes were also prepared at the tracer (186Re) level by
using 186Re-citrate as precursor. Corroboration of the structure at tracer level was achieved by comparative HPLC
studies.
Introduction
equimolar quantities of the tridentate and monodentate coligands
on a suitable TcO3+ precursor.3 This ligand system has been
shown to form complexes of the same structure at the tracer
level (99mTc). Distribution studies in mice demonstrated
significant uptake and retention of these 99mTc complexes in
the brain.4
The coordination chemistry of technetium and rhenium
currently is attracting much attention due to the radionuclide-
based application in radiopharmaceuticals. 99mTc is the radio-
nuclide of choice for diagnostic imaging due to its ideal nuclear
properties (t1/2 ) 6 h, γ ) 140 keV) and wide availability. On
the other hand, 186Re and 188Re as â-emitters (Emax ) 1.1 and
2.1 MeV, respectively) are two of the most promising candidates
for radiotherapy.1 The half-life of 186Re is 90.64 h with a γ-line
of 137 keV (9.5%), and the half-life of 188Re is 17 h with a
γ-line of 155 keV (15%).
Our recent work involves the study of mixed-ligand systems
(3+1 combination) as chelating systems for oxotechnetium. We
have reported previously the synthesis and characterization of
a series of neutral, lipophilic technetium complexes, TcOL1L2,
where L1H2 is a tridentate ligand (SNS donor atom set) and
L2H is a monodentate thiol acting as coligand.2 Formation of
these complexes is based on the simultaneous action of
Rhenium, as technetium’s third-row congener, exhibits many
of the chemical properties of technetium.5 Because of the
analogy in the chemistry of rhenium and technetium and the
recent availability of radionuclides of rhenium, the use of this
ligand combination [3+1, (SNS)(S) donor atom set] may be
further expanded for the preparation of rhenium complexes for
therapeutic applications. We report here the synthesis, structure,
and chemical properties of a representative complex of the
general formula ReOL1L2, where L1H2 ) (C2H5)2NCH2-
CH2N(CH2CH2SH)2 and L2H ) HSC6H4OCH3. Since upon
complexation the N substituent of the tridentate ligand can
assume the syn or anti configuration with respect to the ReO3+
core, two diastereomeric complexes theoretically are possible.6
Indeed, we have successfully isolated the two isomers: syn
(complex 1) with the side chain on nitrogen directed toward
the RedO core and anti (complex 2) with the side chain directed
away from the RedO core (Chart 1). Both complexes were
characterized by elemental analysis and spectroscopic methods.
* Address correspondence to Efstratios Chiotellis, Ph.D., Institute of
Radioisotopes-Radiodiagnostic Products, 15310 Ag. Paraskevi, Athens,
Greece. Telephone +301 6513793. Fax: +301 6543526.
X Abstract published in AdVance ACS Abstracts, October 1, 1996.
(1) (a) Volkert, W.; Ketring, A. J. Nucl. Med. 1991, 32, 174. (b) Deutsch,
E.; Libson, K.; Vanderheyden, J.-L.; Ketring, A. R.; Maxin, H.R. J.
Nucl. Med. Biol. 1986, 13, 465. (c) Fritzeberg, A. R.; Vanderheyden,
J.-L.; Rao, T. N.; Kasina, S.; Eshima, D.; Taylor, A. T. J. Nucl. Med.
1989, 30, 60. (d) DiZio, J. P.; Fiaschi, R.; Davison, A.; Jones, A. G.;
Katzenellenbogen, J. A. Bioconjugate Chem. 1991, 2, 353.
(3) (a) Pietzsch, H.-J.; Spies, H.; Hoffmann, S.; Stach, J. Lipophilic
technetium complexes-V. Inorg. Chim. Acta 1989, 161, 15. (b) Pietzch,
H.-J.; Spies, H.; Hoffmann, S.; Scheller, D. Appl. Radiat. Isotop. 1990,
41, 185. (c) Spies, H.; Johannsen, B.; Pietzsch, H.; Noll, B.; Noll, St.;
Scheunemann, M.; Fietz, T.; Berger, R.; Brust, P.; Leibnitz, P. XI
International Symposium on Radiopharmaceutical Chemistry, Van-
couver, 1995, 319 (d) Spies, H.; Fietz, T.; Glaser, M.; Pietzsch, H.;
Johannsen, B. in Technetium and Rhenium in Chemistry and Nuclear
Medicine 4; Nicolini, M., Bandoli, G., Mazzi, U., Eds.; SGE: Padova,
1995; p 243.
(4) (a) Pirmettis, I.; Papadopoulos, M.; Paschali, E.; Varvarigou, A.;
Chiotellis, E. Eur. J. Nucl. Med. 1994, 21, S7. (b) Pirmettis, I.;
Papadopoulos, M.; Mastrostamatis, S.; Tsoukalas, Ch.; Chiotellis, E.
J. Nucl. Med. 1995, 36, 145P. (c) Pirmettis, I.; Papadopoulos, M.;
Paschali, E.; Varvarigou, A. D.; Chiotellis, E. J. Nucl. Med. 1995,
36, 145P.
(2) (a) Mastrostamatis, S. G.; Papadopoulos, M. S.; Pirmettis, I. C.;
Paschali, E.; Varvarigou, A. D.; Stassinopoulou C. I.; Raptopoulou
C. P.; Terzis, A.; Chiotellis, E. J. Med. Chem. 1994, 37, 3212. (b)
Stassinopoulou, C. I.; Pelecanou, M.; Mastrostamatis, S.; Chiotellis,
E. Magn. Reson. Chem. 1994, 32, 532. (c) Spyriounis, D.; Pelecanou,
M.; Stassinopoulou, C. I.; Raptopoulou, C. P.; Terzis, A.; Chiotellis,
E. Inorg. Chem. 1995, 34, 1077. (d) Mastrostamatis, S.; Pirmettis, I.,
Papadopoulos, M.; Paschali, E.; Raptopoulou, C.; Terzis, A.; Chiotellis,
E. In Technetium and Rhenium in Chemistry and Nuclear Medicine
4; Nicolini, M., Bandoli, G., Mazzi, U., Eds.; SGE: Padova, 1995; p
409. (e) Papadopoulos, M.; Pirmettis, I.; Raptopoulou, C.; Terzis, A.;
Chiotellis, E. In Technetium and Rhenium in Chemistry and Nuclear
Medicine 4; Nicolini, M., Bandoli, G., Mazzi, U., Eds.; SGE: Padova,
1995; p 223. (f) Pirmettis, I.; Papadopoulos, M.; Mastrostamatis, S.;
Raptopoulou, C.; Terzis, A.; Chiotellis, E. Inorg. Chem. 1996, 35,
1685.
(5) Deutsch, E.; Libson, K.; Vanderheyden, J.-L. In Technetium and
Rhenium in Chemistry and Nuclear Medicine 3; Nicolini, M., Bandoli,
G., Mazzi, U., Eds.; Raven Press: New York, 1990; p 119.
S0020-1669(96)00416-8 CCC: $12.00 © 1996 American Chemical Society